Updates

Quantum Pharma - Bid from Clinigen

September 2017

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Quantum soared after reporting that it has received an indicative proposal from SCSW’s other favourite, Clinigen (CLIN; 1124p), regarding a possible offer. The offer is subject to due diligence. Sure Quantum has some overlap and the deal makes sense as Clinigen (a main write up for SCSW at 196p in November ‘12; gain 473%) can use its highly rated paper. Quantum’s primary cash cow is specials, which has seen NHS prescribing volumes under pressure and is price regulated - Clinigen knows this as its Idis business already operates in this area. Quantum’s niche pharmaceutical business is presently marginal, with really only a single key product (a liquid formulation specials of glycopyrronium bromide with >£1m ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

WANdisco - Shares double since March

Scientific Digital - Bolt-on acquisition

Quantum Pharma - Gain since our February write up: 75% (October 2017)

Quantum Pharma (June 2017)

Quantum Pharma - Considerably less flannel from new CEO (February 2017)

Quantum Pharma - Sweep of board and placing (November 2016)

Quantum Pharma (June 2016)

Quantum Pharma (March 2016)

Quantum Pharma - Five more products now approved (November 2015)

Quantum Pharma - Soon-to-be prospective PE of 9.9 (October 2015)

Quantum Pharma (September 2015)

Quantum Pharma - Explosive growth trajectory (June 2015)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X